Onesource Specialty Pharma Share Price | Onesource Specialty Pharma Stock Screener
ONESOURCE
Pharmaceuticals
Share Price NSE
₹1654.30
▼
-17.20 (-1.03%)
Share Price BSE
₹1653.80
▼
-20.00 (-1.19%)
As of July 23, 2026, the Onesource Specialty Pharma share price (NSE: ONESOURCE) is ₹1,654.30 on NSE and ₹1,653.80 on BSE, down 1.03% from the previous close, with shares trading between ₹1,634.00 and ₹1,689.90, and a 52-week range of ₹1,114.00–₹1,995.90.
Analyse ONESOURCE price movement history and track historical price performance.
Use the Onesource Specialty Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Onesource Specialty Pharma Market Cap
₹18,852.36 Cr.
ONESOURCE P/E Ratio (TTM)
-255.96
Onesource Specialty Pharma P/B Ratio
3.24
EPS (TTM)
₹-6.44
Dividend Yield
-
Debt to Equity
0.21
ONESOURCE 52 Week High
₹1995.90
Onesource Specialty Pharma 52 Week Low
₹1114.00
Operating Margin
21.00%
Profit Margin
1.16%
ONESOURCE Revenue (TTM)
₹430.00
EBITDA
₹94.00
Net Income
₹5.00
Total Assets
₹8,210.00
Total Equity
₹5,831.00
Onesource Specialty Pharma Share Price Chart
Screen Onesource Specialty Pharma share price with an interactive chart. Analyse ONESOURCE price trends and volatility across different timeframes.
Onesource Specialty Pharma Company Profile - Fundamental Screener
Screen Onesource Specialty Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for ONESOURCE shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE013P01021
Onesource Specialty Pharma Balance Sheet Screener
Screen ONESOURCE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Total Assets | 8,210 | 7,550 | 1,309 | 2,009 | 2,442 | 1,258 | 972 |
| Current Assets | 1,426 | 1,086 | 176 | 228 | 511 | 99 | 25 |
| Fixed Assets | 2,719 | 6,118 | 863 | 1,361 | 1,231 | 633 | 354 |
| Liabilities | |||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 937 | 556 | 282 | 358 | 621 | 321 | 361 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||||
| Total Equity | 5,831 | 5,881 | 396 | 786 | 1,013 | 776 | 417 |
| Share Capital | 12 | 11 | 4 | 4 | 3 | 2 | 1 |
| Reserves & Surplus | 5,820 | 5,869 | 392 | 781 | 1,009 | 775 | 414 |
Onesource Specialty Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Onesource Specialty Pharma income statement and profit fundamentals.
Analyze ONESOURCE quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Onesource Specialty Pharma share price evaluation.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 430 | 295 | 379 | 333 | 429 | 399 | 338 | 296 | 76 | 88 | 34 | 10 |
| Expenses | 336 | 280 | 269 | 242 | 244 | 351 | 263 | 233 | 76 | 173 | 105 | 80 |
| EBITDA | 94 | 15 | 110 | 91 | 185 | 48 | 76 | 64 | 0 | -85 | -71 | -70 |
| Operating Profit % | 21.00% | 4.00% | 28.00% | 26.00% | 43.00% | 11.00% | 21.00% | 20.00% | -4.00% | -207.00% | -210.00% | -800.00% |
| Depreciation | 72 | 70 | 70 | 68 | 69 | 69 | 68 | 68 | 20 | 20 | 18 | 19 |
| Interest | 23 | 38 | 34 | 28 | 33 | 46 | 45 | 42 | 21 | 26 | 25 | 18 |
| Profit Before Tax | 0 | -93 | 6 | -4 | 83 | -67 | -38 | -47 | -40 | -130 | -114 | -107 |
| Tax | -5 | -4 | -5 | -4 | -16 | 2 | 5 | -41 | 0 | 0 | 0 | 0 |
| Net Profit | 5 | -89 | 11 | 0 | 99 | -69 | -42 | -6 | -40 | -130 | -114 | -107 |
| EPS | 0.40 | -7.74 | 0.92 | -0.02 | 8.61 | -6.31 | -10.13 | -0.51 | -9.67 | -31.32 | -27.37 | 0.00 |
Onesource Specialty Pharma Cash Flow Screener - Liquidity Fundamentals
Screen ONESOURCE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March |
|---|---|---|---|---|---|
| Operating Activities | -68 | -107 | -163 | -416 | -118 |
| Investing Activities | -201 | 511 | -68 | -692 | -207 |
| Financing Activities | 412 | -391 | 118 | 1,162 | 381 |
| Net Cash Flow | 143 | 13 | -112 | 55 | 56 |
Onesource Specialty Pharma Shareholding Pattern Screener
See Onesource Specialty Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Onesource Specialty Pharma promoter holding and ownership changes for ONESOURCE on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec |
|---|---|---|---|---|---|---|
| Promoter Holding | 30.48% | 29.93% | 29.77% | 29.79% | 34.25% | 37.77% |
| FII Holding | 17.50% | 19.24% | 19.39% | 18.69% | 18.54% | 17.44% |
| DII Holding | 20.61% | 18.81% | 18.49% | 18.10% | 18.04% | 12.56% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 12.18% | 12.39% | 12.42% | 13.25% | 12.50% | 13.05% |
| Other Holding | 19.23% | 19.63% | 19.93% | 20.17% | 16.67% | 19.18% |
| Shareholder Count | 79,460 | 84,595 | 87,416 | 87,760 | 82,712 | 98,425 |
Onesource Specialty Pharma Share Dividend Screener - Share Yield Analysis
Check Onesource Specialty Pharma dividend history with payout and yield data.
View Onesource Specialty Pharma dividend details including ex-dates and amounts for ONESOURCE stock.
Onesource Specialty Pharma Stock Index Membership
See which indices include Onesource Specialty Pharma stock.
Check ONESOURCE index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Onesource Specialty Pharma Market Events Screener - Corporate Actions
Get Onesource Specialty Pharma corporate actions including splits, bonuses, and buybacks.
Check Onesource Specialty Pharma stock events that may affect ONESOURCE share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-13 | 2026-05-13 | Quarterly Result Announcement | NA | 5.21% |
| 2026-01-23 | 2026-01-23 | Quarterly Result Announcement | NA | -12.34% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | -1.89% |
| 2025-09-22 | 2025-09-22 | Annual General Meeting | NA | -1.03% |
| 2025-08-04 | 2025-08-04 | Quarterly Result Announcement | NA | -7.04% |
| 2025-05-05 | 2025-05-05 | Quarterly Result Announcement | NA | 0.09% |
| 2025-01-29 | 2025-01-29 | Quarterly Result Announcement | NA | - |
| 2024-02-14 | 2024-02-14 | Change Of Name | NA | - |
Onesource Specialty Pharma Competitors Screener - Peer Comparison
Screen ONESOURCE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 467,031 | 40.90 | 61,674 | 12.69% | 11,565 | 68.02 |
| Divis Laboratories | 196,208 | 75.78 | 11,067 | 13.95% | 2,568 | 71.98 |
| Torrent Pharmaceuticals | 190,500 | 79.75 | 13,886 | 20.34% | 2,138 | 66.68 |
| Cipla | 114,003 | 29.97 | 29,045 | 2.24% | 3,870 | 52.50 |
| Zydus Life Science | 113,050 | 22.27 | 27,658 | 17.64% | 5,026 | 58.19 |
| Lupin | 111,249 | 21.47 | 29,039 | 26.75% | 5,356 | 63.60 |
| Mankind Pharma | 105,661 | 54.93 | 14,636 | 14.85% | 1,938 | 60.75 |
| Dr Reddys Laboratories | 99,276 | 24.22 | 35,059 | 3.90% | 4,158 | 32.84 |
| Aurobindo Pharma | 88,453 | 26.21 | 33,385 | 3.21% | 3,376 | 58.93 |
| Laurus Labs | 85,567 | 96.66 | 6,868 | 22.01% | 890 | 67.71 |
Onesource Specialty Pharma Company Announcements - News Screener
Screen ONESOURCE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - | |
| 2026-07-23 | Board Meeting Intimation for Approval Of The Unaudited Financial Results For The Quarter Ended June 30 2026. | - |
| 2026-07-16 | Onesource Specialty Pharma And Formycon AG Announce Strategic Manufacturing Partnership For Biosimilars | - |
| 2026-07-09 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015 | - |
| 2026-07-08 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-07-02 | Completion Of US-FDA Inspection At Sterile Product Division (SPD) Facility At Bengaluru | - |
| 2026-06-24 | Closure of Trading Window | - |
| 2026-05-19 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-05-19 | General- Update | - |
| 2026-05-16 | General-Update | - |
| 2026-05-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-13 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-13 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-05-13 | Update On Composite Scheme Of Amalgamation | - |
| 2026-05-13 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | - |
| 2026-05-13 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-05-13 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-13 | Board Meeting Outcome for Intimation Of The Outcome Of The Board Meeting Dated May 13 2026 For Approval Of The Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31 2026 | - |
| 2026-05-07 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |